The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ELVN | -14.99% | -81.38% | -28.52% | -9% |
| S&P | +14.18% | +88.25% | +13.47% | +73% |
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded in June 2019 and is headquartered in Boulder, CO.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.06M | 22.5% |
| Market Cap | $1.21B | 0.5% |
| Market Cap / Employee | $18.65M | -19.6% |
| Employees | 65 | 14.0% |
| Net Income | -$20.15M | 13.0% |
| EBITDA | -$25.03M | 7.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $101.73M | 1.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.39M | 355.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -24.41% | 5.0% |
| Return On Invested Capital | -36.32% | -15.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.28M | -8.7% |
| Operating Free Cash Flow | -$13.28M | -8.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.69 | 3.11 | 3.41 | 2.48 | -37.18% |
| Price to Tangible Book Value | 3.69 | 3.11 | 3.41 | 2.48 | -37.18% |
| Enterprise Value to EBITDA | -30.14 | -22.01 | -19.48 | -31.71 | -9.04% |
| Return on Equity | -32.0% | -31.3% | -25.3% | -25.4% | -17.91% |
| Total Debt | $0.00M | $0.37M | $0.38M | $0.39M | 355.29% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
